Adagio Medical Holdings, Inc.

Tickers
ADGM
Headquarters
Not recorded
SEC CIK
0002006986
Website
Not recorded

Closing prices

Latest close, 0.09

Closing prices for ADGM249 stored closes for ADGM from 3 Nov 2025 to 29 Oct 2026. Lowest 0.09 on 29 Oct 2026, highest 1.63 on 14 Apr 2026, latest 0.09 on 29 Oct 2026.Close0.000.501.001.502.003 Nov 20251 May 202629 Oct 2026
249 stored closes, oldest first. End of day, not intraday.

Drugs

No drugs from this company are tracked yet.

FDA-approved applications

No Drugs@FDA application has a sponsor name that matches this company.

Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.

Catalysts

No catalysts yet. Editors add each date together with its source.

Deals

No approved deals involve this company yet.

Reported fundamentals (SEC XBRL)

Latest value of each metric as reported to the SEC
MetricReported valuePeriodFiling
Revenue0 USD 1 Apr 2026 to 30 Jun 2026 FY2026 Q210-Q for Revenue on sec.gov (opens in a new tab)Filed
Net income (loss)−6,717,000 USD 1 Apr 2026 to 30 Jun 2026 FY2026 Q210-Q for Net income (loss) on sec.gov (opens in a new tab)Filed
Research and development expense2,450,000 USD 1 Apr 2026 to 30 Jun 2026 FY2026 Q210-Q for Research and development expense on sec.gov (opens in a new tab)Filed
Operating expenses4,934,000 USD 1 Apr 2026 to 30 Jun 2026 FY2026 Q210-Q for Operating expenses on sec.gov (opens in a new tab)Filed
Cash and cash equivalents7,740,000 USD At 30 Jun 2026 FY2026 Q210-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed
Short-term investments and marketable securitiesNot reported in XBRL filings since 2015
Total liabilities34,299,000 USD At 30 Jun 2026 FY2026 Q210-Q for Total liabilities on sec.gov (opens in a new tab)Filed
Stockholders' equity−415,000 USD At 30 Jun 2026 FY2026 Q210-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed
Common shares outstanding (cover page)22,210,459 shares At 10 Aug 2026 FY2026 Q210-Q for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed

History

Revenue, newest period first
PeriodReported valueFiling
1 Apr 2026 to 30 Jun 2026 FY2026 Q20 USD10-Q filed 11 Aug 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2026 to 31 Mar 2026 FY2026 Q10 USD10-Q filed 12 May 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2025 to 31 Dec 2025 FY20250 USD10-K filed 27 Mar 2026 on sec.gov (opens in a new tab)Filed
1 Jul 2025 to 30 Sep 2025 FY2025 Q30 USD10-Q filed 12 Nov 2025 on sec.gov (opens in a new tab)Filed
1 Apr 2025 to 30 Jun 2025 FY2026 Q20 USD10-Q filed 11 Aug 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2025 to 31 Mar 2025 FY2026 Q10 USD10-Q filed 12 May 2026 on sec.gov (opens in a new tab)Filed
31 Jul 2024 to 30 Sep 2024 FY2025 Q3132,000 USD10-Q filed 12 Nov 2025 on sec.gov (opens in a new tab)Filed
1 Jul 2024 to 30 Jul 2024 FY2025 Q353,000 USD10-Q filed 12 Nov 2025 on sec.gov (opens in a new tab)Filed

The newest 12 periods of each metric are listed; older ones are on sec.gov.

Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.

Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read

SEC filings

SEC filings from Adagio Medical Holdings, Inc., newest first
FormFiledWhat it coversDocument
8-K Current report (8-K) View Current report (8-K) filed 26 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001104659-26-118615 (opens in a new tab)
4Event 27 Sep 2024 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 13 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0002031256-26-000004 (opens in a new tab)
DEF 14AEvent 23 Oct 2026 Proxy statement (DEF 14A) View Proxy statement (DEF 14A) filed 13 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001140361-26-039339 (opens in a new tab)
8-KEvent 25 Sep 2026 Current report (8-K)
  • Unregistered sales of equity securities (Item 3.02)
View Current report (8-K) filed 1 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001104659-26-112887 (opens in a new tab)
8-K Current report (8-K)
  • Costs of exit or disposal activities (Item 2.05)
  • Other events (Item 8.01)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 23 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001104659-26-109821 (opens in a new tab)
8-KEvent 13 Aug 2026 Current report (8-K)
  • Notice of delisting or listing rule failure (Item 3.01)
View Current report (8-K) filed 14 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001104659-26-097242 (opens in a new tab)
8-K Current report (8-K)
  • Regulation FD disclosure (Item 7.01)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 13 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001104659-26-095987 (opens in a new tab)
4Event 16 Jun 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 12 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001792380-26-000002 (opens in a new tab)
4Event 16 Jun 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 12 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0002031256-26-000002 (opens in a new tab)
4Event 16 Jun 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 12 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001665442-26-000002 (opens in a new tab)

Source: SEC EDGAR. Each row links to the filing on sec.gov.

Related news

No recent headlines mention this company.

Last 90 days of Form 4 filings, from 3 Aug 2026 (US Eastern dates).

Buys code P
None in this period
Sells code S
None in this period
Other all other codes
None in this period

Last transaction:

Insider filings are public records and are not a recommendation. Source: SEC EDGAR.

Sources

Nothing on this page is investment advice.